Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly EBT Margin came in at 56.38% in Q1 2026, up 598.0% YoY from 8.08% in Q1 2025, and up 19.67% on a QoQ basis from 47.11% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 9 years of EBT Margin data on file, last reported at 56.38% in Q1 2026.
- Quarterly EBT Margin rose 598.0% year-over-year to 56.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.66% (up 132.0% YoY) and the FY2025 annual result came in at 48.14%, up 416.0% from the prior year.
- EBT Margin grew to 56.38% in Q1 2026, from 47.11% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 56.38% in Q1 2026 to a low of 37.03% in Q3 2023.
- A 5-year average of 41.88% and a median of 47.11% in 2025 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin sank 8246 bps — and 2024, when it soared 8148 bps.
- Tracing CPRX's EBT Margin over 5 years: stood at 54.33% in 2022, then retreated by 22 bps to 42.24% in 2023, then climbed by 24 bps to 52.31% in 2024, then declined by 10 bps to 47.11% in 2025, then rose by 20 bps to 56.38% in 2026.
- The last three EBT Margin figures came in at 56.38% (Q1 2026), 47.11% (Q4 2025), and 47.87% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn | 56.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.38% |
| Dec 31, 2025 | 47.11% |
| Sep 30, 2025 | 47.87% |
| Jun 30, 2025 | 47.28% |
| Mar 31, 2025 | 50.41% |
| Dec 31, 2024 | 52.31% |
| Sep 30, 2024 | 44.45% |
| Jun 30, 2024 | 45.46% |
| Mar 31, 2024 | 29.53% |
| Dec 31, 2023 | 42.24% |
| Sep 30, 2023 | -37.03% |
| Jun 30, 2023 | 48.72% |
| Mar 31, 2023 | 43.71% |
| Dec 31, 2022 | 54.33% |
| Sep 30, 2022 | 45.43% |
| Jun 30, 2022 | 53.18% |
| Mar 31, 2022 | 40.52% |
| Dec 31, 2021 | 33.45% |
| Sep 30, 2021 | 39.14% |
| Jun 30, 2021 | 43.72% |